Score Overview
Explore the 2021 public Archive ranking →
Where Genmab AS has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- GMAB
2020: 14.4% · 2021: 4.0% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 35.36 | — |
1 Year2025-09-26 | $ 29.07 | 21.64% |
5 Years2021-09-28 | $ 42.05 | -15.91% |
10 Years2016-09-28 | $ 17.21 | 105.49% |
All Time2009-06-01 | $ 3.77 | 9x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | All Time2009-06-01 |
|---|---|---|---|---|---|
| Price | $ 35.36 | $ 29.07 | $ 42.05 | $ 17.21 | $ 3.77 |
| Return | — | 21.64% | -15.91% | 105.49% | 9x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in DKK
| Year | |||
|---|---|---|---|
| TTM | kr 4.13B | kr 788M | kr 1.50B |
| 2025 | kr 3.72B | kr 963M | kr 1.71B |
| 2024 | kr 21.52B | kr 7.84B | kr 21.10B |
| 2023 | kr 16.47B | kr 4.35B | kr 28.13B |
| 2022 | kr 14.50B | kr 5.45B | kr 22.32B |
| 2021 | kr 8.41B | kr 2.95B | kr 19.33B |
| 2020 | kr 10.11B | kr 4.75B | kr 16.07B |
| 2019 | kr 5.36B | kr 2.16B | kr 10.97B |
| 2018 | kr 3.02B | kr 1.47B | kr 6.10B |
| 2017 | kr 2.36B | kr 1.10B | kr 5.42B |
| 2016 | kr 1.81B | kr 1.18B | kr 3.92B |
| 2015 | kr 1.13B | kr 763M | kr 3.49B |
| 2014 | kr 850M | kr 301M | kr 2.66B |
| 2013 | kr 663M | kr 112M | kr 1.55B |
| 2012 | kr 484M | -kr 487M | kr 1.50B |
| 2011 | kr 350M | -kr 596M | kr 1.10B |
| 2010 | kr 582M | -kr 321M | kr 1.64B |
| IPO2009 | kr 586M | -kr 1.01B | kr 1.27B |
Genmab AS fundamental performance
Between 2020 and 2025, revenue declined from kr 10.11B to kr 3.72B and net income declined from kr 4.75B to kr 963M. Revenue increased in 4 of those 5 years; net income in 2.
Across Genmab AS's full reported history, from 2009 to 2025, revenue grew from kr 586M to kr 3.72B and net income went from -kr 1.01B to kr 963M. Revenue increased in 76% of the years measured; net income in 65%.
Genmab AS currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.
Membership
Continue GMAB’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
